Acute Myeloid Leukemia Clinical Trials

157 studies are recruiting for acute myeloid leukemia in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 7

1. Two Step Haplo With Radiation Conditioning

   This phase II clinical trial evaluates whether a modified modality of conditioning reduces treatment-related mortality (TRM) in patients who undergo a hematopoietic stem cell transplant (HSCT) for a hematological malignancy. HSCT is a curative therapy for many hematopoietic malignancies, however th…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadephia, Pennsylvania

   Run by

   Thomas Jefferson University

   See if you can join NCT05031897 on ClinicalTrials.gov

2. Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome

   This study is being performed to develop assays to determine the impact of the therapy patients receive for treatment of AML or MDS and to determine if these tests can identify those patients who are at a greater risk for having their disease relapse.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Rochester Medical Center, Rochester, New York

   Run by

   University of Rochester

   See if you can join NCT01311258 on ClinicalTrials.gov

3. Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

   Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   5 in total

   Run by

   Vincerx Pharma, Inc.

   See if you can join NCT06034275 on ClinicalTrials.gov

4. Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML

   This is a phase I/II dose escalation study designed to determine the safety and estimate the efficacy of UD-NK cells combined with FLA chemotherapy in patients age 1-24.99 with relapsed or refractory acute myeloid leukemia. PRIMARY OBJECTIVE: I. To determine the safety and recommended phase II dose…

   Stage

   Phase 1

   Ages

   1 to 24

   Site

   Nationwide Children's Hospital, Columbus, Ohio

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05503134 on ClinicalTrials.gov

5. Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

   This phase II trial evaluates the effect of azacitidine or decitabine and venetoclax in treating patients with acute myeloid leukemia that has not been treated before (treatment naive) or has come back (relapsed). Chemotherapy drugs, such as azacitidine, decitabine, and venetoclax, work in differen…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UCSF-Fresno, Clovis, California

   Locations

   4 in total

   Run by

   Brian Jonas

   See if you can join NCT04905810 on ClinicalTrials.gov

6. A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

   This is an open-label, dose escalation study to evaluate the safety, toxicity, and pharmacokinetics (PK) as well as preliminary efficacy of BTX-A51 capsules in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study will be done i…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope National Medical Center, Duarte, California

   Locations

   3 in total

   Run by

   Edgewood Oncology Inc.

   See if you can join NCT04243785 on ClinicalTrials.gov

7. Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

   An open-label, phase I, multi-center study to determine in relapsed/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients the recommended dose of CYAD-02 after a non-myeloablative preconditioning chemotherapy followed by a potential CYAD-02 consolidation cycle for…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Kansas Cancer Center, Fairway, Kansas

   Locations

   5 in total

   Run by

   Celyad Oncology SA

   See if you can join NCT04167696 on ClinicalTrials.gov